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Background: Colorectal cancer (CRC) is the most common cancer in Europe with a mortality rate of almost 50%.
The prognosis of patients is largely determined by the clinical and pathological stage at the time of diagnosis.
Population screening has been shown to reduce CRC-related mortality rate. Most screening programs worldwide
rely on fecal immunochemical testing (FIT). The effectiveness of a FIT screening program is not only influenced by
initial participation rate, but also by program adherence during consecutive screening rounds. We aim to evaluate
the participation rate in and yield of a third CRC screening round using FIT.
Methods and design: Four years after the first screening round and two years after the second round, a total
number of approximately 11,000 average risk individuals (50 to 75 years of age) will be invited to participate in a
third round of FIT-based CRC screening. We will select individuals in the same target area as in the previous
screening rounds, using the electronic database of the regional municipal administration registrations. We will invite
all FIT-negatives and all non-participants in previous screening rounds, as well as eligible first time invitees who
have moved into the area or have become 50 years of age.
FITs will be analyzed in the special technique laboratory of the Academic Medical Center of the University of
Amsterdam. All FIT-positives will be invited for a consultation at the outpatient clinic. In the absence of contra-
indications, a colonoscopy will follow at the Academic Medical Center or at the Flevohospital. The primary outcome
measures are the participation rate, defined as the proportion of invitees that return a FIT in this third round of FIT-
screening, and the diagnostic yield of the program.
Implications: This study will provide precise data on the participation in later FIT screening rounds. This enables to
estimate the effectiveness of CRC screening programs that rely on repeated FIT- screening, such as the one that will
be implemented in the Netherlands in 2013.Background
Colorectal cancer (CRC) is the most common cancer in
Europe. In 2008, there were an estimated 436,000 new
cases of CRC and 212,000 deaths [1]. Currently, about
five percent of persons at average risk develop CRC [2].
The prognosis of patients with CRC is largely influenced
by the cancer stage at diagnosis [3]. Timely detection of
cancer and removal of its precursor lesions (i.e.* Correspondence: i.stegeman@amc.nl
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distribution, and reproduction in any mediumadenomas) has been shown to result in a lower CRC in-
cidence and mortality [4,5]. Based on these arguments,
screening for CRC meets the Wilson and Jungner cri-
teria for population screening [6].
Several methods are available for population screening
for CRC, which can be broadly itemized into stool tests
and structural exams [7]. Stool tests include the guaiac,
the immunochemical and DNA-marker tests. Structural
exams comprise colonoscopy, sigmoidoscopy and CT
colonography. The fecal occult blood test (FOBT) and
sigmoidoscopy are the only screening methods with a
documented mortality reduction over a follow-up period
of 10 years. A meta-analysis of FOBT-based screeningtral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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tion in FOBT screening after several screening rounds
[8]. A large randomized controlled trial in which sub-
jects received either once-only sigmoidoscopy screening
or no screening reported a 31% CRC-related mortality
reduction in the screening group [9].
The Council of the European Union has recom-
mended population screening for CRC by FOBT [10].
Several EU member states have adopted this advice, al-
though some have implemented non-population based
screening programs using other strategies, such as Pol-
and and Germany. In the Netherlands, the effectiveness
of FOBT screening has been intensively studied in the
past 5 years. Two large randomized controlled trials
were performed in the Amsterdam, Nijmegen en Rotter-
dam region, comparing participation rates of invitational
population-based screening using either guiac-FOBT or
immunochemical FOBT (FIT) [11,12]. Both trials
demonstrated significantly higher participation rates in
FIT than in guiac-FOBT based screening: 60% and 62%
versus 47% and 50%. In addition, detection rates of
advanced neoplasia (CRC and advanced adenomas) were
higher in FIT screening than in guiac-based screening:
2.4% and 5.5% versus 1.1% and 1.2%. The effectiveness
of population screening is largely determined by the par-
ticipation rate, not only on participation in the initial
screening round, but also on participation in consecutive
rounds (“program adherence”). Two years after the first
screening round in Amsterdam, 10,265 individuals
received an invitation to participate in a second round
FIT- screening [13]. Compared to the first round, a sig-
nificant lower overall participation rate was observed in
the second round (43% vs 52%). Overall, 86% of first
round participants participated again in the second
round and of the previous non-participants, 21% did
participate in the second round [14].
Although second round participation in this program
was lower, a further decrease is not necessary. In three
consecutive screening rounds by guiac-based FOBT
screening in Scotland, for example, participation
remained stable: 55% participated in a first round, 53%
in a second round, and 55% in a third round [15]. Two
years after the second round and four years after the first
round of FIT screening, members of the same dynamic
Amsterdam cohort will once again receive an invitation
to participate in population screening by FIT. We will
document the level of participation and the yield of




To evaluate the participation rate in and yield of a third
round of FIT-based colorectal cancer screening in theNetherlands, two years after the second round and four
years after the first round.
Secondary objectives
We will compare overall participation rates in the third
round with those in the first and second round and will
compare participation rates in previous participants and
non-participants of the first and/or second round. In
addition, we will evaluate the complication rate of FIT
screening, including follow-up colonoscopy in FIT-
positives, and compare these to the results of the first
and second round of screening. Also we will evaluate the
number and cancer stage of interval cancers in the co-
hort during the 3 consecutive rounds.
Study design and population
This study is a designed as a dynamic cohort study. The
cohort consists of approximately 11,000 men and women
between 50 and 75 years of age at average risk for CRC,
living in the Amsterdam region, the same area as in the
first and the second round. We will identify cohort mem-
bers using the electronic database of the regional munici-
pal administration registration (Gemeentelijke Basis
Administratie (GBA)).
Institutionalized people will be excluded from partici-
pation. Participants in the first or second round who
have previously tested positive will not be invited. We
will instruct all invitees with rectal blood loss and or
change in bowel habits not to participate in screening.
Invitation procedure
Eligible cohort members will be invited between July
2011 and December 2011. All invitations will be sent out
by the regional Comprehensive Cancer Centre Amster-
dam using the same centralized invitation program as in
previous screening rounds (ICOLON). This institution is
also involved in the existing population-based screening
programs in the region including breast and cervical
cancer screening. Invitees will receive a pre-
announcement, followed by an invitation kit 2 weeks
later by postal mail containing an invitation letter, an in-
formation leaflet, an immunochemical FOBT, a test in-
struction and a frequently asked questions (FAQ) card.
A reminder will be sent two and eight weeks, after the
initial invitation.
Information brochure
The information brochure covers information relevant
to colorectal cancer screening. It contains facts on CRC
in general, instructions how to perform the FIT, infor-
mation regarding false-negative and false-positive
results, details of the follow-up colonoscopy for FIT-
positives, and information on the benefits and harms of
screening. This leaflet is an updated version of the leaflet
Stegeman et al. BMC Gastroenterology 2012, 12:73 Page 3 of 4
http://www.biomedcentral.com/1471-230X/12/73used in the second round. The leaflet is based on the
principles of informed-choice, aiming designed to enable
all invited persons to make a well-informed decision
whether or not to participate.
Informed consent
An informed consent form is sent together with the FIT.
Before analyzing the stool sample, we will check if the
informed consent is enclosed and signed. If the informed
consent is not correctly available, the stool sample will
not be analyzed and the participant will be notified by
mail and asked to complete the informed consent.
FIT
For this study the same FIT as the one used in previous
rounds will be used (OC-sensor; Eiken Chimical Co,
Tokyo, Japan). This test provides a quantitative measure-
ment of human hemoglobin in stool. The FIT consist of
a probe attached to a cap, which fits a collection tube
containing hemoglobin stabilizing buffer. Participants
are instructed to collect one bowel movement and to
sweep the tip of the probe several times through the
feces and to insert the probe into the collection tube
afterwards. No diet restrictions are advised. In the spe-
cialized laboratory of the Academic Medical Center, the
returned FITs will be processed using the OC- Sensor -
automated instrument. According to previous rounds a
subject is considered positive at a cut-off level of 50 ng
hemoglobin per milliliter feces.
Test results
The test result will be sent to the participant and his or
her general practitioner by regular mail. In case of a
positive test result, the participant will be invited for a
consultation at the screening center at the Academic
Medical Center in Amsterdam or the Flevo Hospital in
Almere. During the consultation, the need for a follow-
up colonoscopy will be discussed and the individuals ex-
clusion criteria and/or contra-indications for colonos-
copy are checked. Test positive Invitees with end-stage
disease and a life-expectancy of less than 5 years, and
those who have had a complete colonoscopy in the pre-
vious two years, will not be invited for colonosopy. In
absence of contra-indications, a colonoscopy will be
planned within two weeks after the consultation. In case
of a negative test result, no follow up is advised.
Colonoscopy
Colonoscopies are performed at the Academic Medical
Center or at the Flevohospital. All colonoscopies will be
performed by experienced endoscopists (≥ 200 colonos-
copies) according to the prevailing quality guidelines
[16]. Colonoscopy quality indicators will be recorded on
a case record form. In case of polyps or cancer,endoscopic removal of the lesions will be attempted dur-
ing the same procedure. If endoscopic removal is not
possible, biopsies will be obtained and histopathological
assessment will provide a definitive diagnosis.
Lesions and pathology
Data on location, size, macroscopic aspect, morphology
type of procedure (diagnostic or therapeutic) and endo-
scopic assessment of radicality will be recorded for all
lesions detected during colonoscopy. Lesions will be
evaluated by an experienced gastrointestinal pathologist
according to the Vienna criteria [17]. All lesions will be
classified as adenoma (tubular, tubulovillous, villous),
serrated (hyperplastic, sessile serrated adenoma, trad-
itional serrated adenoma), adenocarcinoma or miscellan-
eous. Dysplasia will be defined as either low-grade or
high-grade.
Follow-up after colonoscopy
Colonoscopy findings will be discussed with the partici-
pant by telephone or at the outpatient clinic, if desired,
two weeks after the colonoscopy. If the colonoscopy is
negative, no follow up is advised. In case of polyps, sur-
veillance colonoscopy is advised according to the Dutch
surveillance guidelines [18]. In case of CRC, the patient
will be invited at the outpatient clinic and referred to a
gastroenterologist or surgeon for further treatment. The
general practitioner will be informed about the colonos-
copy result by mail.
Cancer registry
All invitees are linked to The Netherlands Cancer Regis-
try, which collects data of new cancer patients, such as
tumor type, incidence date and stage [19]. Using this
registry, we can identify interval carcinomas in the three
consecutive screening rounds.
Ethical approval
Ethical approval was obtained from the Dutch Health
Council (The Hague, The Netherlands).
Data analysis
Participation rate is defined as the number of invitees
returning a FIT relative to the number of all eligible
invitees. The third round participation rate will be com-
pared with those of the two previous screening rounds.
Participation rates in subgroups of participants and non-
participants of previous screening rounds will be com-
pared. Among third round invitees the following sub-
groups can be defined: (1) non-participants in the first
and the second round; (2) participants in the first and
the second round; (3) invitees who participated in the
first but did not in the second round; (4) second round
participants who did not participate in the first round
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the first round (6) second round non-participants who
were not invited for the first round and (7) first time
invitees. Screening yield is calculated by dividing the
total number of participants with detected advanced
neoplasia by the number of participants (per-protocol
analysis) and the total number of invitees (intention-to-
screen analysis). Advanced neoplasia is defined as a CRC
or an advanced adenoma. An advanced adenoma is
defined as an adenoma ≥ 10 mm, an adenoma with ≥ 25%
villous histology or an adenoma with high grade dyspla-
sia. We will express participation rates and diagnostic
yield as proportions and present estimates with corre-
sponding confidence intervals. We will compare propor-
tions by Chi-square statistic. We will evaluate the
number and stage of interval cancers. Interval cancers
will be defined as the proportion of cancer diagnosed in
first and second round participants outside the screen-
ing. Interval cancers will be identified via cross-linkage
of the screening pilot with the Dutch cancer registry.
Cancer stage at diagnosis and location will be retrieved
via the registry. Descriptive statistics will be used to
analyze the interval cancers. Chi-square test statistic will
be used to analyze the distribution of cancer stage and
location between screen detected cancers of the first,
second and third round and interval cancers.Implications
This study will provide information on participation and
yield in the third round of a FIT- based CRC screening
program. Participation rate and determinants of partici-
pants will be compared with the first and the second
screening round. This study will also provide informa-
tion on interval cancers in FIT based screening, in a
third round of biannual pilot screening. As FIT is gener-
ally preferred over guiaic-FOBT in most countries FIT
will become the test of choice. The study results will en-
able us to estimate the effectiveness of a FIT-based CRC
screening program with 2-yearly rounds, such as the one
that will be implemented in the Netherlands in 2013.Abbreviations
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